Oxycyte will be manufactured at Hospira’s Clayton, North Carolina, facility which specializes in emulsion technology.
Hospira will formulate, fill, finish and label Oxycyte to meet clinical good manufacturing practice standards required for use of drugs in human patients. The amount of Oxycyte supplied by Hospira will be sufficient to meet any expected demand for the foreseeable future. The financial terms of the supply agreement were not disclosed.
Chris Stern, chairman and CEO of Oxygen Biotherapeutics, said: “This agreement connects us to a first-tier contract manufacturer and superbly reliable supplier who will provide us with all the Oxycyte we need to grow the company. As I’ve previously stated, our strategy is to license marketing rights for individual indications, yet always control the supply of our compound and be able to profit from sales of Oxycyte to licensees.”